CRISPR Screen Points to Autophagy Blockade Plus PARP Inhibitor Against Lung Cancer

Small cell lung cancer is among the deadliest and hardest-to-treat malignancies, and a new preclinical study suggests a way to sharpen one of its experimental weapons. Using a genome-wide CRISPR dropout screen, researchers identified the loss of genes that restrain the mTOR signaling pathway—particularly TSC1 and TSC2—as a mechanism that makes small cell lung cancer cells unusually vulnerable to PARP inhibitor drugs. Building on that discovery, they showed that blocking autophagy, the cellular recycling process controlled downstream of mTOR, synergizes with a next-generation PARP inhibitor in cell lines and in mouse models of the disease. The work, published as a Brief Report in Cancer & Metabolism, positions the autophagy inhibitor GNS561 alongside the PARP1-selective agent AZD5305 as a combination worth pursuing clinically.

The rationale for the screen stems from an unmet clinical need. Small cell lung cancer accounts for roughly 15 percent of lung cancer cases, yet drives disproportionate mortality: five-year overall survival sits below 10 percent, and about two thirds of patients already have extensive-stage disease at diagnosis. First-line platinum chemotherapy with etoposide produces striking initial response rates of 60 to 80 percent, but relapse is nearly universal, leaving a median survival under 10 months. The addition of anti-PDL1 immunotherapies such as atezolizumab and durvalumab extended median survival by only about two months, which the authors describe as a significant remaining gap in treatment options.

PARP inhibitors entered the small cell lung cancer conversation after a landmark 2012 study showed that PARP1, a key enzyme in base excision repair, is elevated in these tumors relative to other cancer types. PARP inhibition causes single-strand DNA breaks to accumulate, and PARP1 trapping on DNA can convert that damage into double-strand breaks during replication—a vulnerability exploited most successfully in cancers with defective homologous recombination repair. But small cell lung cancer has confounded expectations: patient responses vary widely and do not track cleanly with homologous recombination status or PARP1 expression. In a phase I trial of the PARP inhibitor talazoparib in relapsed extensive-stage disease, responses were inconsistent. That variability is precisely what motivated the search for genetic determinants of sensitivity.

The team, led by Benjamin H. Lok with colleagues at institutions in Toronto, ran their dropout screens in two small cell lung cancer cell lines, SBC5 and NCI-H82, engineered to express Cas9 and transduced with the Toronto KnockOut v1 guide library. Cells were treated with olaparib at doses calibrated to kill more than 99 percent of the population, and guide RNAs that vanished from the treated arm relative to controls were flagged as sensitizing hits at a false discovery rate threshold of 0.05. The top-ranked genes converged on a surprising node: TSC1, TSC2, STK11, and components of the GATOR1 complex including DEPDC5, NPRL2, and NPRL3. All of these act as negative regulators of mTORC1 signaling and, indirectly, as positive regulators of autophagy. Many outranked the BRCA2 positive control, which showed weak sensitizing activity in these particular screens, while non-targeting and PARP1 controls ranked near the bottom as expected.

To validate the finding, the researchers used shRNA knockdown of TSC1 and TSC2 in SBC5, SHP77, and, for comparison, HEK293T cells. Knocking down either gene significantly lowered the olaparib IC50: in SBC5 cells, IC50 fell from 13.8 micromolar in controls to 6.2 micromolar for TSC1 knockdown and 4.3 micromolar for TSC2 knockdown, both with p-values below 0.0001. In SHP77 cells, IC50 dropped from 37 micromolar to 10 micromolar with TSC1 knockdown. The effect extended beyond small cell lung cancer lines—HEK293T cells showed IC50 reductions from 4.1 to roughly 1.2 to 1.4 micromolar—hinting the mechanism may generalize. Western blotting confirmed that TSC-deficient cells accumulated LC3B-II, a marker of stalled autophagic flux, when autophagy was pharmacologically blocked, linking the genetic hits to the autophagy pathway.

That link suggested a therapeutic logic. mTORC1 suppresses autophagy, and prior work in other cancers has shown that tumor cells ramp up autophagy in response to PARP inhibition as a survival strategy. If autophagy is the escape route, closing it should trap the cancer cells. The team tested two autophagy inhibitors: chloroquine, an established lysosomotropic agent, and GNS561, a novel and more potent lysosomotropic compound under clinical investigation. In starvation-induced autophagy assays, both drugs caused LC3B-II accumulation, but GNS561 produced far stronger LC3B puncta accumulation by immunofluorescence and showed monotherapy IC50 values of 0.7 to 2.4 micromolar across small cell lung cancer lines, compared with greater than 5 micromolar for chloroquine.

For the PARP arm, the researchers selected AZD5305, a next-generation inhibitor with enhanced PARP1 specificity designed to reduce PARP2-mediated toxicity. Small cell lung cancer cell lines again displayed the field’s familiar heterogeneity, with AZD5305 IC50 values ranging from 5 nanomolar in NCI-H1048 to more than 25 micromolar in SHP77. Yet when paired with GNS561, the combination showed additive to mildly synergistic effects across cell lines, with most synergistic area scores between 5.08 and 8.77 and maximum synergy scores from 10.10 to 14.76—scores above 10 are conventionally considered synergistic. Notably, the older chloroquine–olaparib pairing failed to synergize, with area scores of just 0.12 to 0.81, suggesting the newer agents’ greater potency matters. A mechanistically distinct approach reinforced the point: ULK-101, an inhibitor of autophagy induction via the ULK1 kinase, also synergized with AZD5305, with area scores reaching 24.63, indicating that autophagy targeting in general, not just lysosomal disruption, is the operative strategy.

The in vivo results provided the study’s strongest evidence. NSG mice engrafted with NCI-H82 or SHP77 cells received vehicle, AZD5305 alone, GNS561 alone, or the combination by oral gavage five days per week. In NCI-H82 xenografts, combination therapy reduced average tumor weight by 280 milligrams versus vehicle, corresponding to 50.3 percent tumor growth inhibition; in SHP77 xenografts the reduction was 250 milligrams, or 69.3 percent inhibition. Kaplan-Meier analysis showed significantly improved survival for the combination arm compared with vehicle in both models, with no significant benefit from either single agent alone. Toxicity signals appeared limited: no mouse reached the humane endpoint of 20 percent body weight loss, and the few animals exceeding 15 percent weight loss recovered quickly after brief treatment pauses. Western blots confirmed target engagement, with reduced PARylation in AZD5305-treated tumors.

One intriguing wrinkle emerged from the pharmacodynamics. After 48 hours of combination treatment, tumors accumulated LC3B-II, confirming autophagy blockade, but at the volumetric endpoint after prolonged treatment, LC3B-II had returned to baseline in both GNS561 and combination arms. The authors speculate that alternate mechanisms may clear autophagosomes under long-term inhibition, making the timing of combination dosing a critical variable for optimization. They also acknowledge a key limitation: the study did not investigate how autophagy inhibition interacts with DNA damage response pathways, though work in other cancers suggests active autophagy promotes high-fidelity homologous recombination repair while its inhibition pushes cells toward error-prone repair—a hypothesis requiring direct testing in small cell lung cancer.

Both drugs are already in clinical development elsewhere—GNS561 in trials against cholangiocarcinoma and hepatocellular carcinoma, with favorable lung localization in rat distribution studies, and AZD5305 as a next-generation PARP inhibitor—which lowers the barrier to combination testing. The authors caution, appropriately, that these are cell line and xenograft findings in immunodeficient mice, not human efficacy data, and past clinical trials combining autophagy inhibition with radiotherapy in small cell lung cancer were terminated for poor accrual. Still, the convergence of an unbiased genetic screen, mechanistic validation, and in vivo efficacy makes a coherent case: for a disease with so few options, deliberately disabling the cancer cell’s recycling machinery while bombarding its DNA repair pathway is a combination now deserving of clinical scrutiny.

Subject of Research: Preclinical identification of autophagy inhibition as a combination strategy with PARP inhibitors in small cell lung cancer

Article Title: CRISPR screen identifies autophagy inhibition (GNS561) as a PARP inhibitor (AZD5305) combination strategy in small cell lung cancer

Article References: Yu, T., Barayan, R., Song, L., Venkatasubramanian, V., Tamakuwala, J., Nair, S. N., Philip, V., & Lok, B. H. (2026). CRISPR screen identifies autophagy inhibition (GNS561) as a PARP inhibitor (AZD5305) combination strategy in small cell lung cancer. Cancer & Metabolism, 14(1), Article 30. https://doi.org/10.1186/s40170-026-00443-4

Image Credits: AI Generated

DOI: 10.1186/s40170-026-00443-4

Keywords: small cell lung cancer, CRISPR screen, PARP inhibitors, autophagy, GNS561, AZD5305, mTOR, TSC1, TSC2, xenograft models, drug synergy, preclinical study